Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China. Fosun Pharma has built a firm root in China and developed a global operation strategy, with pharmaceutical manufacturing and R&D being the most significant and core business segment, together with a strong presence in medical devices and diagnostics, healthcare services, pharmaceutical distribution, and retail.

With R&D innovation as a core driving factor, Fosun Pharma continues to optimize its pharmaceutical operations across both innovative and generic drugs. The company has established international R&D centers for excellence in areas such as innovative small molecule drugs, high-value generic drugs, biologics, and cell therapy.

Under the guidance of our 4-IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma follows the brand concept of Innovation for Good Health and strives to be a leading enterprise in the global pharmaceutical and healthcare markets.

Incorporated in 1994, Tasly Holding Group has now developed to an internationalized and high-tech cooperation, engaging in the pan-health industry with the biological medicine industry as the core business, health industry, and medical service as two supporting businesses.              

Guided by ancient Chinese civilization, Tasly is devoted to the philosophy “seeking for harmonization between human and nature, improving humankind’s life quality” . With the mission of “to share the joy of health with all”, Tasly aims to become the No. 1 in modern biological pharmaceuticals and leader of the integrated health industry in China. By now, Tasly has set up a pan-health industry line, which contains six core industries，including the bio-pharmaceutical industry, health products industry, herbs industry, medical industry, health management industry, and children education industry.

Aiming to realize TCM globalization, Tasly has been sticking to develop the international market since its foundation. By now,  more than 30 types of preparation products in 8 medical categories of Tasly have been put into the global market. And the export routes cover 23 countries in America, Europe, Africa, and Asia. With the distribution network spreading to more than 40 countries, Tasly’s distributor members have almost reached a million in the world. In recent years, Tasly has been listed in the top 10 of TCM exporters in China. And in 2016, Tasly Pharm. Co., Ltd was named the Top 500 of Chinese Enterprises released by the US Fortune magazine.

In September 2002, SHINVA successfully went public at the Shanghai Stock Exchange. It is now the chairman unit of China Association for Medical Devices Industry (CAMDI). We unshakably walk the way of a healthy industry, technical innovation and capital operation, now being the leading medical enterprise in China that is based on medical instruments and equipment, pharmaceutical equipment and preventive medicine service and can provide customers with the main 9 production lines: CSSD integrated solutions, pharmaceutical computer integrated solutions, radiotherapy integrated solutions, digital operating room integrated solutions, integrated dental solutions, medical, environmental protection integrated solutions, experiment animal safeguard integrated solutions, in vitro diagnostic reagents and instruments and biomedical materials and supplies. Among them, the quality and market of the CSSD integrated solutions, pharmaceutical equipment integrated solutions, and radiotherapy integrated solutions both rank the front in China. Every year we have many new products that come into the market.     

Now we have 14 state-level products. We have gained the famous trademark of China and are the first domestic medical enterprise that owns a state-level enterprise technical center. Shandong province is the center of development, manufacturing, marketing, and management, and we have two core areas: Shanghai and Beijing, forming our basic layout. Standing at the new developing stage of history, facing new chances, SHINVA will always advance with the times, act with self-confidence, innovation, and hard work.

KPC Pharmaceuticals, Inc (‘KPC’, 600422 SH) was established in March 1951 and floated on the Shanghai Stock Exchange in December 2000. With its considerable professional experience in the pharmaceutical industry, the company is listed as one of the new key national high-tech companies and one of the Top 100 companies in the Chinese medical industry. The company’s brands, such as Luotai®, Tianxuanqing®, Artemedine®, Artem®, and Arco® , earned the company a good reputation both at home and abroad.

KPC is a pharmaceutical company that focused on innovative natural botanical drugs and integrated R&D, production, marketing, commercial wholesales, and international marketing. Its business scope covers Traditional Chinese Medicine, chemical medicine, and medicinal circulation. Companies owned by KPC include the Kunming Traditional Chinese Medicine Co. Ltd., Kingtide Notoginseng Industry Co. Ltd., Xishuangbanna Pharmaceutical Co. Ltd., Kunming Pharmaceutical Commercial Co. Ltd., Kunming Baker Norton Pharmaceutical Co. Ltd., Nukus Botanic Technology Co. Ltd., Kunming Yinnuo Medical Technology Co. Ltd., and Beijing Holley-Cotec Pharmaceuticals Co. Ltd. KPC also boasts a large-scale manufacturing center, Xuesaitong drug research institute, and postdoctoral workstation. Situated in the National Biological Industry Base of the Kunming High-tech Zone, the “KPC Bio-Pharmaceutical Science and Technology Park” will be a large-scale, professional and international biomedical park, taking the lead both at home and abroad.

Based on Yunnan’s abundant plant resources, KPC has developed more than 40 new natural botanical drugs, including the artemether series, Panax Notoginseng series, Gastrodine series, special Chinese medicines, and special ethnic drugs. With multiple national patents, KPC has filled several gaps in the pharmaceutical industry both at home and abroad. Being highly renowned and popular in terms of treatments for cardio-cerebral-vascular diseases, nervous system diseases, and malaria, KPC has made positive and significant contributions to the health of humans.

KPC’s unique core competitive advantages include its outstanding R&D ability, abundant product resources, robust integrated manufacturing system, internationally compatible quality management system, and its international marketing team. In the future, following the principle “From nature; For Human Health”, KPC will develop into a global pharmaceutical supplier focusing on cardio-cerebral-vascular disease and chronic disease treatment. At the same time, it will continue striving to be a leading and globally famous brand in terms of cardio-cerebral-vascular drugs.